Registration for the COVID-19 vaccine in India for people between the ages of 18 and 44 will take effect from 4pm today (Wednesday, April 28). This will be phase 3 of a vaccination campaign in India that will expand existing vaccinations for people aged 45 and over.
Registration for the COVID-19 vaccine is compulsory and requires qualified people to have official proof of Indian identity such as a PAN card or other government ID. India last reported more than 350,000 cases a day, the highest in the world.
The government will begin the process of registering people between the ages of 18 and 44 at 4pm via the CoWIN portal, as well as the Aarogya Setu and Umang applications, the official MyGovIndia account posted on Twitter on Wednesday.
Registration was initially announced from midnight (12am), but was postponed to 4pm. At the time of writing, Aarogya Setu’s official account wrote on Twitter that although CoWIN library registration is now open, scheduling of immunizations should be set by national governments and private immunization centers, so it may take longer before you can actually make an appointment.
After registration, the all-eligible immunization campaign will start from May 1. However, it will be about the availability of vaccines. Nominations for public and private institutions will depend on how many vaccines are ready for May 1 to vaccinate people over the age of 18, a MyGovIndia account posted on twitter.
How to register for the COVID-19 vaccine?
Online registration of the COVID-19 vaccine is compulsory for people between the ages of 18 and 44, according to the FAQ section of the CoWIN section. This means that unlike people aged 45 and over, people between the ages of 18 and 44 are unlikely to qualify for immediate enrollment (travel nomination).
You need to have a mobile number to register for the COVID-19 vaccine online. The government also needs valid proof of India ID. This could be your Aadhaar card, driver’s license, PAN card, passport, pension pass letter, NPR smart card, or voting ID card (e-elector photo ID card). As mentioned, you can register on the CoWIN website, or through the Aarogya Setu or Umang app.
Steps to register for COVID-19 vaccination via CoWIN port
When registration of the COVID-19 vaccine for people aged 18-44 years begins, eligible citizens will be able to register for an appointment online. Here’s how to put one together for use with your home.
- Visit the CoWIN website and click Register / Sign In.
- Type in your mobile number and press the Find OTP button. One-time password (OTP) will access your phone.
- Enter the OTP you received on your phone and click Confirm.
- Now enter details such as your name, gender, and year of birth. Click Register.
- Click on the Schedule next to the name of the registered person to book a rental period.
- Enter your PIN and click Search. You will see available resources for your PIN code.
- You can also search for a vaccine center by selecting your country and region.
- Select the center and date and time of vaccination, then hit Confirm.
- You can add up to four family members with one subscription. However, it is important to point out that if one person aged 45 or over and others between the ages of 18 and 44 want to schedule a combined meeting time, there will be only private paid immunization centers or vaccination centers according to national government policy. .
Steps to register for COVID-19 injection with the Aarogya Setu app
If you do not want to use the CoWIN website with a Web browser, you can use the Aarogya Setu app on your phone to sign up for the COVID-19 vaccine. Below are the steps you can take to register using the app.
- Open the Aarogya Setu app.
- Go to the CoWIN tab from the Home screen.
- Select Vaccine Registration and enter your phone number to get OTP.
- Tap Confirm. You will be directed to the vaccination registration page.
- Now follow the same steps as mentioned above for registration with the CoWIN portal.
- The vaccine campaign currently includes two COVID-19 drugs, Covaxin developed by Bharat Biotech and Covishield based in Hyderabad developed by Oxford-AstraZeneca and developed by the Serum Institute of India (SII).